I agree that this site is using cookies. You can find further informations here.
X
Michał Taszner
42  results:
Search for persons X
?
1

Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory ..:

Zinzani, Pier Luigi ; Trněný, Marek ; Ribrag, Vincent...
eClinicalMedicine.  62 (2023)  - p. 102131 , 2023
Link: https://doi.org/10.1016/..
 
?
2

P1083: ODRONEXTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY FO..:

Taszner, Michał ; Luminari, Stefano ; Cho, Seok-Goo...
HemaSphere.  7 (2023)  S3 - p. e214536e , 2023
Link: https://doi.org/10.1097/..
 
?
3

P1103: OBINUTUZUMAB INDUCTION AND MAINTENANCE IN PATIENTS W..:

Wróbel, Tomasz ; Kalicinska, Elzbieta ; Maciej Zaucha, Jan...
HemaSphere.  7 (2023)  S3 - p. e4339598 , 2023
Link: https://doi.org/10.1097/..
 
?
4

PB2279: TRIAL IN PROGRESS: ODRONEXTAMAB, A CD20×CD3 BISPECI..:

Cho, Seok-Goo ; Kim, Tae Min ; Taszner, Michał...
HemaSphere.  7 (2023)  S3 - p. e4155242 , 2023
Link: https://doi.org/10.1097/..
 
?
5

P017: The role of baseline bulk and dissemination measures ..:

Taszner, Michal ; Romanowicz, Grzegorz ; Knopińska-Posłuszny, Wanda...
HemaSphere.  6 (2022)  - p. 8-9 , 2022
Link: https://doi.org/10.1097/..
 
?
6

Ofatumumab with iphosphamide, etoposide and cytarabine for ..:

Paszkiewicz‐Kozik, Ewa ; Michalski, Wojciech ; Taszner, Michał...
British Journal of Haematology.  198 (2022)  1 - p. 73-81 , 2022
Link: https://doi.org/10.1111/..
 
?
7

In Silico Designed Gain-of-Function Variants of Complement ..:

Urban, Aleksandra ; Majeranowski, Alan ; Stasiłojć, Grzegorz...
Cancers.  14 (2022)  5 - p. 1270 , 2022
Link: https://doi.org/10.3390/..
 
?
8

High efficacy of BGD (bendamustine, gemcitabine, and dexame..:

Swoboda, Ryszard ; Giebel, Sebastian ; Knopińska-Posłuszny, Wanda...
Annals of Hematology.  100 (2021)  7 - p. 1755-1767 , 2021
Link: https://doi.org/10.1007/..
 
?
9

Correction to: High efficacy of BGD (bendamustine, gemcitab..:

Swoboda, Ryszard ; Giebel, Sebastian ; Knopińska-Posłuszny, Wanda...
Annals of Hematology.  100 (2021)  7 - p. 1919-1919 , 2021
Link: https://doi.org/10.1007/..
 
?
10

Monitoring of the Complement System Status in Patients With..:

Felberg, Anna ; Taszner, Michał ; Urban, Aleksandra...
Frontiers in Immunology.  11 (2020)  - p. , 2020
Link: https://doi.org/10.3389/..
 
?
11

Mutations resulting in the formation of hyperactive complem..:

Felberg, Anna ; Urban, Aleksandra ; Borowska, Anna...
Cancer Immunology, Immunotherapy.  68 (2019)  4 - p. 587-598 , 2019
Link: https://doi.org/10.1007/..
 
?
12

Pixantrone, etoposide, bendamustine, rituximab (P[R]EBEN) a..:

Długosz-Danecka, Monika ; Hus, Iwona ; Puła, Bartosz...
Pharmacological Reports.  71 (2019)  3 - p. 473-477 , 2019
Link: https://doi.org/10.1016/..
 
?
13

Zastosowanie infuzyjnego schematu chemioterapii DA-EPOCH w ..:

Taszner, Michał ; Szymańska, Agata ; Bieniaszewska, Maria
Acta Haematologica Polonica.  49 (2018)  2 - p. 85-91 , 2018
Link: https://doi.org/10.2478/..
 
?
14

Plerixafor for patients who fail cytokine-or chemotherapy-b..:

Giebel, Sebastian ; Oborska, Sylwia ; Romejko-Jarosinska, Joanna...
Acta Haematologica Polonica.  49 (2018)  4 - p. 234-239 , 2018
Link: https://doi.org/10.2478/..
 
?
15

Stem cell mobilization in patients with dialysis‐dependent ..:

Waszczuk‐Gajda, Anna ; Drozd‐Sokołowska, Joanna ; Boguradzki, Piotr...
Journal of Clinical Apheresis.  33 (2017)  3 - p. 249-258 , 2017
Link: https://doi.org/10.1002/..
 
1-15